Clinical Considerations for Implanted Neurological Devices in Patients Undergoing Hyperbaric Oxygen Therapy: A Case Report and Review of Manufacturer Guidelines

Simone Schiavo (), Connor T. A. Brenna, Anuj Bhatia, William J. Middleton and Rita Katznelson
Additional contact information
Simone Schiavo: Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON M5G 1E2, Canada
Connor T. A. Brenna: Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON M5G 1E2, Canada
Anuj Bhatia: Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON M5G 1E2, Canada
William J. Middleton: Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON M5G 1E2, Canada
Rita Katznelson: Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON M5G 1E2, Canada

IJERPH, 2023, vol. 20, issue 9, 1-9

Abstract: Patients with implanted medical devices are increasingly referred for hyperbaric oxygen therapy (HBOT), and the safety of exposing some of these devices to hyperbaric environments has not previously been explored. There is a paucity of evidence surrounding the management of implanted neurological devices such as neurostimulators and intrathecal drug delivery (IDD) pumps in the context of HBOT. However, these devices can be expected to harbor unique risks; for example, vacant space in the reservoir of an implanted IDD pump may change in pressure and volume during the compression and decompression phases of HBOT, resulting in a damaged or dysfunctional device. We present the case of a 27-year-old woman with cerebral palsy referred for HBOT to manage a necrotizing soft tissue infection cultured from a dehiscent abdominal wound at the previous implantation site of an intrathecal baclofen pump. An HBOT protocol was ultimately chosen in partnership with the patient and her family, but treatment was not performed due to a paucity of evidence that the implanted IDD pump could safely withstand hyperbaric exposure. In this review, we have synthesized manufacturer recommendations regarding the management of implanted neurological devices before, during, and after HBOT to inform future decision-making in this setting. Among these recommendations, we highlight that neurostimulators should be switched off for the duration of HBOT and implanted pumps should be refilled prior to each treatment session to minimize empty reservoir space.

Keywords: hyperbaric oxygen treatment; implanted devices; intrathecal drug delivery pumps; neurostimulators; risk assessment; case report (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/9/5693/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/9/5693/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:9:p:5693-:d:1137889

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().